All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Validation of updated ELN 2022 risk stratification in adult patients with AML
Bookmark this article
|
Previous studies validating the ELN 2022 classification were based on heterogeneous patient cohorts receiving varying treatment regimens.1 Results from a large retrospective cohort study validating the prognostic value of the ELN 2022 classification in 1,570 patients with newly diagnosed AML treated with cytarabine-based chemotherapy were published in Blood Advances by Ruhnke et al.1 |
| Key learnings |
| Compared with the ELN 2017 and 2022 classifications, risk group allocation was revised for 22% of patients, with most being reclassified into the intermediate (46%) and adverse (33%) risk groups. |
| Reallocation based on ELN 2022 resulted in distinct 5-year EFS (40%, 21%, and 8%), RFS (49%, 32%, and 23%), and OS (53%, 32%, and 13%) rates between the favorable, intermediate, and adverse risk groups, respectively. |
| In the adverse-risk group, OS rates differed between mutational groups; the 5-year OS rate was 21% in patients with MR gene mutations, but only 3% in patients with TP53 mutations. |
| This large cohort analysis found the ELN 2022 risk classification to improve prognostic accuracy in patients with newly diagnosed AML receiving intensive treatment, although further evaluation of its prognostic value is needed in patients with MR gene mutations. |
Abbreviations: AML, acute myeloid leukemia; EFS, event-free survival; ELN, European LeukemiaNet; MR, myelodysplasia-related; OS, overall survival; RFS, relapse-free survival.
- Ruhnke L, Bill M, Zukunft S, et al. Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia. Blood Adv. 2024. Online ahead of print. DOI:10.1182/bloodadvances.2024013304
Your opinion matters
32 votes - 34 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox